Alps Advisors Inc Amylyx Pharmaceuticals, Inc. Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.62 - $2.71 $79,206 - $132,500	-48,893 Reduced 35.11%	90,357 $171,000
Q1 2024 May 14, 2024	BUY	$2.71 - $19.57 $242,604 - $1.75 Million	89,522 Added 180.02%	139,250 $395,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $386 - $590	32 Added 0.06%	49,728 $731,000
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $5,713 - $7,410	316 Added 0.64%	49,696 $909,000
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $120,089 - $179,848	5,724 Added 13.11%	49,380 $1.07 Million
Q1 2023 May 10, 2023	SELL	$27.71 - $40.93 $34,803 - $51,408	-1,256 Reduced 2.8%	43,656 $1.28 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $1.34 Million - $1.76 Million	44,912 New	44,912 $1.66 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.